WO2010034198A1 - 糖蛋白中去除/灭活病毒的方法 - Google Patents
糖蛋白中去除/灭活病毒的方法 Download PDFInfo
- Publication number
- WO2010034198A1 WO2010034198A1 PCT/CN2009/071971 CN2009071971W WO2010034198A1 WO 2010034198 A1 WO2010034198 A1 WO 2010034198A1 CN 2009071971 W CN2009071971 W CN 2009071971W WO 2010034198 A1 WO2010034198 A1 WO 2010034198A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycoprotein
- virus
- hormone
- human
- variant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- HCG, FSH, LH are all composed of two subunits, a chain and ⁇ chain, through non-covalent bonds, wherein their ⁇ subunits are identical, with 92 amino acids, molecular weight of about 14500D, positions 52 and 78.
- the asparagine is an amino acid that undergoes quinone-glycosylation.
- the ⁇ subunit of HCG has 145-147 amino acids with a molecular weight of 22200-39000D, and the asparagine at positions 13 and 30 and the positions 121, 127, 132, and 145 are where glycosylation occurs.
- the ⁇ subunit of FSH consists of 11 1 amino acids with a molecular weight of approximately 18000D, and asparagine at positions 7 and 24 is a ⁇ -glycosylated amino acid.
- the ⁇ subunit of LH consists of 121 amino acids with a molecular weight of approximately 14800D.
- the amount of HBV in the glycoprotein is negative by PCR at a concentration of 1 mg/mL.
- the fluorescent quantitative PCR method extracts nucleic acid (DNA or RNA) in a sample by a lysate and an extract, and then amplifies a specific viral nucleic acid sequence by a nucleic acid polymerase chain reaction, and performs color development by fluorescence.
- the titer of the virus was determined.
- PCR detection can be performed using instruments and reagents routine in the art, such as, but not limited to, the fluorescent quantitative PCR detection system of Hangzhou Dahe Thermomagnetic Electronics Co., Ltd., HBV, HCV, HIV nucleic acid amplification fluorescence quantification of Shenzhen Pico Bioengineering Co., Ltd. Detection kit.
- the glycoprotein is selected from the group consisting of chorionic gonadotropin, follicle stimulating hormone, luteinizing hormone, menopausal gonadotropin, or a mixture thereof.
- the human chorionic gonadotropin is human chorionic gonadotropin or a variant thereof, selected from human urine-derived and/or recombinant human chorionic gonadotropin or a variant thereof;
- a menopausal gonadotropin is a human menopausal gonadotropin or a variant thereof, selected from human urine-derived and/or recombinant human menopausal gonadotropins or variants thereof;
- the follicular steroid hormone is a human follicular stimulating hormone or a variant thereof, selected from human urine-derived and/or recombinant human follicular stimulating hormone or a variant thereof;
- the luteinizing hormone is human luteinizing hormone or a variant thereof, selected from human urine-derived and/or recombinant Human luteinizing hormone or a variant thereof.
- the organic solution treatment is selected from the group consisting of forming a precipitate and/or a suspension stirring treatment
- glycoprotein hormone is selected from the group consisting of chorionic gonadotropin, follicle stimulating hormone, luteinizing hormone, menopausal gonadotropin, or a mixture thereof.
- the human chorionic gonadotropin is human chorionic gonadotropin or a variant thereof, selected from human urine-derived and/or recombinant human chorionic gonadotropin or a variant thereof;
- a menopausal gonadotropin is a human menopausal gonadotropin or a variant thereof, selected from human urine-derived and/or recombinant human menopausal gonadotropins or variants thereof;
- the follicular steroid hormone is a human follicular stimulating hormone or a variant thereof, selected from human urine-derived and/or recombinant human follicular stimulating hormone or a variant thereof;
- the luteinizing hormone is human luteinizing hormone or a variant thereof, selected from human urine-derived and/or recombinant Human luteinizing hormone or a variant thereof.
- the organic solution described in the step (a) is a 30-100 V / V / organic solvent / aqueous solution.
- the organic solution is 70 to 100 v/v% of an organic solvent/aqueous solution.
- the organic solvent is selected from the group consisting of ethanol, methanol, acetone, or diethyl ether. In another preferred embodiment, the organic solvent is selected from the group consisting of ethanol or acetone.
- the weight ratio of the glycoprotein to the organic solution in step) is 0.5 to 2 g: 15 to 60 ml.
- the glycoprotein and the organic solution have a weight to volume ratio of 0.7 to 1.5 g: 20 to 40 ml.
- the glycoprotein is treated with an organic solution at minus 30 ° C to 30 ° C for 0.5 minutes to 6 hours in step (a).
- the glycoprotein is treated with an organic solution at a temperature of from 20 ° C to 20 ° C for from 1 minute to 4 hours in the step (a).
- the microporous membrane in the step (b) is selected from an ultrafiltration membrane having a pore diameter of 1000 Dalton or more, a virus removal membrane having a pore diameter of 1 to 100 nm, or a pore diameter of 0.1 to 1 ⁇ m. Bacterial filtration membrane.
- the microporous membrane in the step (b) is selected from an ultrafiltration membrane having a pore diameter of 100,000 dalton or more, a virus removal membrane having a pore diameter of 10 to 80 nm, or a pore diameter of 0.2 to 0.8 ⁇ m. Bacterial filtration membrane.
- the ion exchange chromatography in the step (c) is carried out under the conditions of ⁇ ⁇ 5 - 10.
- the ion exchange chromatography in the step (c) is carried out under the conditions of ⁇ 6-8.
- a pharmaceutical composition comprising a virus-free glycoprotein provided by the invention and a pharmaceutically acceptable carrier. Accordingly, the present invention provides a process for removing/inactivating a virus suitable for treating a glycosylated protein of infertility, and obtaining a safe and effective drug.
- the inventors have extensively and intensively studied and surprisingly found that the removal/inactivation of sugar can be achieved by any combination of one or all of the steps of organic solution treatment, microporous membrane filtration and ion exchange chromatography.
- the purpose of the virus in the protein is to be such that the virus is removed/inactivated under mild conditions and the activity of the target-glycosylated protein is retained.
- the inventors have completed the present invention.
- the inventors noted that the treatment of organic solvents such as ethanol or acetone can inactivate the virus and have no effect on the activity of HCG, HMG, FSH, LH.
- organic solvents such as ethanol or acetone
- suitable microporous membrane filtration techniques not only allows for the retention of viral particles, but also allows the target to be filtered from the membrane for the purpose of separating the target from the virus.
- the inventors unexpectedly discovered during the test that as long as the appropriate conditions are controlled, the virus can be adsorbed on the ionic resin by ion chromatography, and the target is not adsorbed, thereby achieving the purpose of removing the virus in the target. .
- the virus can be effectively removed/inactivated, thereby obtaining a safe and reliable product.
- glycoprotein and “glycosylated protein” are used interchangeably and are selected from one or more of the following combinations: chorionic gonadotropin (CG), follicle ⁇ Ij hormone (follicule-stimulating hormone, FSH), luteotropic hormone (LH), human menopausal gonadotropin (HMG).
- CG chorionic gonadotropin
- FSH follicle ⁇ Ij hormone
- LH luteotropic hormone
- HMG human menopausal gonadotropin
- chorionic gonadotropin and "CG” are used interchangeably and refer to a hormone that has the same or similar structure and function as native CG incorporated during the preparation or acquisition of a material containing FSH.
- the method for removing and/or inactivating viruses in proteins provided by the present invention can be used in addition to glycoproteins for glycoprotein compositions, including glycoproteins and pharmaceutically/food-acceptable Carrier.
- the term "pharmaceutically acceptable carrier” refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
- the term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Sciences, Mack Pub. Co., N.J. 1991.
- the steps described are organic solution treatment, microporous membrane treatment, and ion exchange chromatography.
- the organic solution treatment is carried out by mixing a glycoprotein with an organic solution to form a precipitate or mixing and stirring into a suspension to inactivate the virus.
- the mixing temperature is from 30 ° C to 30 ° C, preferably from 20 V to 20 ° C; the mixing or mixing time is from 0.5 to 6 hours, preferably from 1 minute to 4 hours;
- the weight ratio of the protein to the organic solution is 0.5 - 2 g: 15 - 60 ml, preferably 0.7 - 1.5 g: 20 - 40 ml;
- the organic solution is 30 - 100 v /v% of an organic solvent/water solution, preferably 70-100 v/v% of an organic solvent/water solution;
- the organic solvent is selected from the group consisting of ethanol, methanol, acetone, or diethyl ether, preferably selected from the group consisting of ethanol or acetone.
- the ion exchange chromatography treatment is to pass a solution having a glycoprotein concentration of 15 to 60 mg/ml (preferably 20 to 40 mg/ml) through an ion exchange resin, and the virus is generally adsorbed on the resin, and the glycoprotein is adsorbed. As the eluent flows out, the virus is removed and/or inactivated.
- the solution has a pH of 5-10, preferably pH 6-8, such as phosphate, acetate or Tris buffer.
- Ion exchange resins conventional in the art can be used, such as, but not limited to, a weak anion exchange resin, preferably DEAE Sephad e X .
- Viruses that are removed and/or inactivated by the methods of the invention are well known in the art, such as, but not limited to, HIV, HAV, HBV, HCV, porcine parvovirus.
- the above-mentioned features mentioned in the present invention, or the features mentioned in the embodiments, may be arbitrarily combined. All of the features disclosed in the present specification can be used in combination with any of the compositions, and the various features disclosed in the specification can be Replace with any alternative feature that provides the same, equal or similar purpose. Therefore, unless otherwise stated, the disclosed features are only a general example of equivalent or similar features.
- the main advantages of the invention are:
- the method provided by the present invention is safe and efficient.
- the method provided by the invention has mild conditions and is suitable for industrial production.
- the invention will now be further elucidated in connection with specific embodiments. It is to be understood that the examples are not intended to limit the scope of the invention.
- the experimental methods in which the specific conditions are not specified in the following examples are generally carried out according to the conditions described in the conventional conditions, for example, Sambrook et al., Molecular Cloning: Laboratory Hand M (New York: Col d Spring Harbor Laboratory Pres s, 1989). Or according to the conditions recommended by the manufacturer. All percentages and parts are by weight unless otherwise stated.
- the indicator viruses selected for the validation experiments have different physicochemical properties that can be used to analyze the contamination of the product.
- HIV-1 is a retrovirus (globular) belonging to the family Retroviridae (80-100 nm in diameter). This lentivirus is sensitive to heat and extreme pH and ruptures under the action of a lipid solvent and a detergent. Can be used as a model virus for HIV-2. Detection is carried out by its ability to amplify and induce syncytia formation in susceptible cells.
- the pseudorabies virus is a lipid-encapsulated DNA virus (spherical type) belonging to the herpesvirus family. This virus is sensitive to heat at low protein concentrations and sensitive to extreme pH and lipid solvents. It can be detected by its ability to amplify and cause cytopathic effects in susceptible cells.
- Bovine diarrhea virus is a lipid enveloped RNA virus (multisphere type) belonging to the family Flaviviridae (diameter 40-60nm). This infectious virus is relatively heat-labile, sensitive to organic solvents, unstable in acid and stable in alkali. Can be used as a model virus for HCV. It is detected by its ability to amplify and cause cytopathic effects in susceptible cells.
- Porcine parvovirus is a non-lipid enveloped DNA virus (icosahedral) belonging to the Parvoviridae (18-24 nm in diameter). This parvovirus is resistant to extreme heat, is stable in a lipid solvent, and is relatively resistant to acidic pH. Can be used as a model virus for parvovirus B19. It is detected by its characteristics of proliferation in susceptibility cells and cytopathic effects.
- HAV is a non-lipid enveloped virus belonging to the picornavirus family (27 nm in diameter).
- the virus is relatively thermostable and resistant to organic solvents and non-ionic detergents and is stable under acidic pH conditions. It can be detected by its ability to amplify and cause cytopathic effects in susceptible cells.
- CRFK cat, kidney source, Felis catus cells containing penicillin (50 iu / ml), streptomycin (5 ( ⁇ g / ml), 1% non-essential amino acids and 10% fetal bovine serum, and supplemented with lysine KGlutamax I) was cultured in EMEM medium. During the virus analysis, the cells were also maintained in the above medium.
- NBL-1 bovine kidney origin, Bos taurus cells containing penicillin (50iu / ml), streptomycin (50 ⁇ ⁇ / ⁇ 1) and 5% horse serum, supplemented with histidine and salts I (Glutamax I) in EMEM Culture in medium. During the virus analysis, the cells were also maintained in the above medium.
- ST wine testis origin
- penicillin 50iu / ml
- streptomycin 50 ⁇ ⁇ / ⁇ 1
- 10% fetal calf serum and DMEM medium supplemented with a histidine salt I (Glutamax I) culturing .
- Glutamax I histidine salt I
- FRhK-4 rhesus monkey kidney origin, Macaca mulatta cells containing penicillin (50iu / ml), streptomycin (50 ⁇ ⁇ / ⁇ 1) and 10% fetal calf serum and supplemented with glutamine I (Glutamax I) culture in DMEM medium. During the virus analysis, the cells were maintained in the same medium, but the fetal bovine serum concentration was reduced to 2%.
- Virus preparation rhesus monkey kidney origin, Macaca mulatta
- Pseudorabies virus is prepared by infecting monolayer cultured CRFK cells. After the cells were infected, the culture was observed until significant cytopathic phenomena were observed. The infected cells are subjected to aseptic conditions, freeze-thawed, lysed, centrifuged, and finally the supernatant is harvested.
- Bovine diarrhea virus was prepared by infecting monolayer cultured NBL-1 cells. After the cells were infected, the culture was observed until significant cytopathic phenomena were observed. The infected cells are subjected to aseptic conditions, freeze-thawed, lysed, centrifuged, and finally the supernatant is harvested.
- Porcine parvovirus is prepared by infecting ST cells cultured in monolayers. After the cells were infected, they were cultured until significant cytopathic effects were observed. The infected cells are frozen, thawed, lysed, and centrifuged under sterile conditions, and the supernatant is finally harvested.
- HAV was prepared by infecting monolayer-cultured FRhK-4 cells. After the cells were infected, they were cultured until significant cytopathic phenomena were observed. The infected cells are lysed under aseptic conditions, freeze-thawed, centrifuged, and finally harvested.
- HIV-1 determines titer by syncytium production assay. Pseudorabies virus, bovine diarrhea virus, and porcine parvovirus were all determined by TCID50 determination. Cytotoxicity test
- the virus reduction was better than 10 4 .
- the virus reduction was 2.35 1 ( ⁇ 10 and 3.00 logl0 respectively). Therefore, this step can be considered to play a certain role in improving the safety of HMG production and preventing the contamination of non-lipid enveloped viruses.
- the remaining sample was filtered through a humidified Pall VF DV 20 filter at a maximum pressure of 30 psi. Collect the filtrate in another container.
- the filter was washed with 5 ml of a pH 7.0 ⁇ 0.1 ammonium acetate buffer at a maximum pressure of 30 psi (2070 mPa). The volume of the filtrate was measured, and 1 ml was sampled to determine the virus infection rate.
- Typical examples of the production of 10,000 bottles of HCG lyophilized injection and containing 1000 IU of HCG per bottle are as follows:
- each bottle contained 1000 IU of HCG and 30 mg of mannitol.
- the above solution was placed in a vial, 0.575 mL per bottle, and lyophilized.
- each bottle contained 75 IU FSH, 75 IU LH and 10 mg lactose.
- the above solution was dispensed into an ampoule, 0.575 mL per bottle, and lyophilized.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Water Supply & Treatment (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011527187A JP2012503596A (ja) | 2008-09-24 | 2009-05-26 | 糖タンパク質におけるウイルスの除去/不活性化方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102003437A CN101397339B (zh) | 2008-09-24 | 2008-09-24 | 糖蛋白中去除/灭活病毒的方法 |
CN200810200343.7 | 2008-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010034198A1 true WO2010034198A1 (zh) | 2010-04-01 |
Family
ID=40516200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/071971 WO2010034198A1 (zh) | 2008-09-24 | 2009-05-26 | 糖蛋白中去除/灭活病毒的方法 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2012503596A (zh) |
KR (1) | KR20110076908A (zh) |
CN (1) | CN101397339B (zh) |
WO (1) | WO2010034198A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10906953B2 (en) | 2015-06-26 | 2021-02-02 | Ferring B.V. | Methods of purification and/or viral inactivation |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101397339B (zh) * | 2008-09-24 | 2012-07-25 | 上海天伟生物制药有限公司 | 糖蛋白中去除/灭活病毒的方法 |
CN102675414A (zh) * | 2011-03-08 | 2012-09-19 | 上海天伟生物制药有限公司 | 糖蛋白中去除/灭活朊病毒的方法 |
CN112301004B (zh) * | 2020-10-30 | 2022-08-05 | 苏州良辰生物医药科技有限公司 | 一种灭活猪细小病毒的方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1262278A (zh) * | 1999-01-26 | 2000-08-09 | Ibsa生物化学研究股份有限公司 | 分离和纯化促卵泡激素和黄体生成激素的方法 |
CN1302818A (zh) * | 2000-12-12 | 2001-07-11 | 上海惠海生化制品厂 | 一种人绒毛膜促性腺激素及其制备方法 |
CN1404485A (zh) * | 2000-02-22 | 2003-03-19 | 应用研究系统Ars股份公司 | 人绒毛膜促性腺激素的纯化方法及由这种方法纯化的重组人绒毛膜促性腺激素 |
CN1415628A (zh) * | 2002-08-14 | 2003-05-07 | 上海天伟生物制药有限公司 | 一种提取人尿黄体生成素的方法 |
CN1587276A (zh) * | 2004-07-23 | 2005-03-02 | 南昌市万华生化制品有限公司 | 高纯度尿卵泡刺激素的纯化及生产工艺 |
CN1958603A (zh) * | 2005-11-04 | 2007-05-09 | 上海天伟生物制药有限公司 | 一种人绒毛膜促性腺素的纯化方法 |
CN101307103A (zh) * | 2007-09-11 | 2008-11-19 | 上海天伟生物制药有限公司 | 一种卵泡刺激素的纯化方法 |
CN101347613A (zh) * | 2008-09-17 | 2009-01-21 | 上海天伟生物制药有限公司 | 几乎不含亚基的糖蛋白的组合物及其制备方法 |
CN101397339A (zh) * | 2008-09-24 | 2009-04-01 | 上海天伟生物制药有限公司 | 糖蛋白中去除/灭活病毒的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1287138B1 (it) * | 1996-11-07 | 1998-08-04 | Ibsa Inst Biochimique Sa | Procedimento per la separazione e purificazione di fsh e lh |
CN1199642A (zh) * | 1997-05-16 | 1998-11-25 | Asta药物股份公司 | 治疗不育症的lhrh-拮抗剂 |
CN1308673A (zh) * | 1998-05-07 | 2001-08-15 | 变更染色体医疗公司 | 通过同源重组修饰FSHβ基因的表达 |
US6365395B1 (en) * | 2000-11-03 | 2002-04-02 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
AU2004228847B2 (en) * | 2003-04-09 | 2010-06-17 | Km Biologics Co., Ltd. | Process for producing albumin preparation |
JP2006151840A (ja) * | 2004-11-26 | 2006-06-15 | Kyowa Hakko Kogyo Co Ltd | ウイルスの除去方法 |
-
2008
- 2008-09-24 CN CN2008102003437A patent/CN101397339B/zh active Active
-
2009
- 2009-05-26 WO PCT/CN2009/071971 patent/WO2010034198A1/zh active Application Filing
- 2009-05-26 KR KR1020117007297A patent/KR20110076908A/ko active Search and Examination
- 2009-05-26 JP JP2011527187A patent/JP2012503596A/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1262278A (zh) * | 1999-01-26 | 2000-08-09 | Ibsa生物化学研究股份有限公司 | 分离和纯化促卵泡激素和黄体生成激素的方法 |
CN1404485A (zh) * | 2000-02-22 | 2003-03-19 | 应用研究系统Ars股份公司 | 人绒毛膜促性腺激素的纯化方法及由这种方法纯化的重组人绒毛膜促性腺激素 |
CN1302818A (zh) * | 2000-12-12 | 2001-07-11 | 上海惠海生化制品厂 | 一种人绒毛膜促性腺激素及其制备方法 |
CN1415628A (zh) * | 2002-08-14 | 2003-05-07 | 上海天伟生物制药有限公司 | 一种提取人尿黄体生成素的方法 |
CN1587276A (zh) * | 2004-07-23 | 2005-03-02 | 南昌市万华生化制品有限公司 | 高纯度尿卵泡刺激素的纯化及生产工艺 |
CN1958603A (zh) * | 2005-11-04 | 2007-05-09 | 上海天伟生物制药有限公司 | 一种人绒毛膜促性腺素的纯化方法 |
CN101307103A (zh) * | 2007-09-11 | 2008-11-19 | 上海天伟生物制药有限公司 | 一种卵泡刺激素的纯化方法 |
CN101347613A (zh) * | 2008-09-17 | 2009-01-21 | 上海天伟生物制药有限公司 | 几乎不含亚基的糖蛋白的组合物及其制备方法 |
CN101397339A (zh) * | 2008-09-24 | 2009-04-01 | 上海天伟生物制药有限公司 | 糖蛋白中去除/灭活病毒的方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10906953B2 (en) | 2015-06-26 | 2021-02-02 | Ferring B.V. | Methods of purification and/or viral inactivation |
Also Published As
Publication number | Publication date |
---|---|
JP2012503596A (ja) | 2012-02-09 |
CN101397339A (zh) | 2009-04-01 |
KR20110076908A (ko) | 2011-07-06 |
CN101397339B (zh) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11207397B2 (en) | Virus purification | |
US11684669B2 (en) | CpG-adjuvanted SARS-CoV-2 virus vaccine | |
El-Fakharany et al. | Potential activity of camel milk-amylase and lactoferrin against hepatitis C virus infectivity in HepG2 and lymphocytes | |
KR102474663B1 (ko) | 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법 | |
JP2013531503A (ja) | 細胞培養におけるウイルス生産中に外来性媒介体を取り除くための方法 | |
NZ225583A (en) | Process for purifying hepatitis a virions (hav) | |
WO2008073490A1 (en) | Purification of influenza viral antigens | |
KR102336158B1 (ko) | 돼지유행성설사병바이러스 및 돼지로타바이러스에 대한 백신 조성물 | |
CA2859916A1 (en) | Purification of herpes virus | |
WO2010034198A1 (zh) | 糖蛋白中去除/灭活病毒的方法 | |
TW202330924A (zh) | 新型冠狀病毒mRNA疫苗及其製備方法與用途 | |
EP3121268B1 (en) | Methods for purification of a virus produced in vitro and clearance assay for the virus | |
Makovitzki et al. | Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate | |
CN102631673A (zh) | 口蹄疫疫苗浓缩纯化方法 | |
US20230272350A1 (en) | Method of purifying whole virus particles | |
JP2024516309A (ja) | コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法 | |
JP2003522740A (ja) | 感染性疾患を治療する方法 | |
US20220323537A1 (en) | USE OF INTERFERENCE PEPTIDE IN PREPARATION OF ANTI-SARS-CoV-2 MEDICAMENT | |
US12005111B2 (en) | Zika virus vaccine | |
WO2012119558A1 (zh) | 糖蛋白中去除/灭活朊病毒的方法 | |
CN117999088A (zh) | 冠状病毒和流感病毒组合物和其使用方法 | |
CN117083078A (zh) | 一种人乳头瘤病毒病毒样颗粒疫苗的稳定制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09815568 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011527187 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117007297 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09815568 Country of ref document: EP Kind code of ref document: A1 |